Checkpoint Therapeutics (NASDAQ:CKPT) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital assumed coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note released on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $9.00 price objective on the stock.

Several other research firms also recently weighed in on CKPT. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Lake Street Capital boosted their price target on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $3.20 on Monday. Checkpoint Therapeutics has a 1 year low of $1.38 and a 1 year high of $4.50. The company has a market cap of $156.27 million, a price-to-earnings ratio of -1.74 and a beta of 1.36. The firm has a fifty day moving average of $3.64 and a 200-day moving average of $2.87.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Analysts predict that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 268,432 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now owns 1,032,754 shares in the company, valued at $4,141,343.54. This represents a 20.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO James F. Oliviero III sold 220,230 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares in the company, valued at $10,797,690.54. This represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Checkpoint Therapeutics

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Checkpoint Therapeutics during the third quarter worth approximately $30,000. XTX Topco Ltd bought a new stake in shares of Checkpoint Therapeutics in the second quarter valued at approximately $34,000. Gladstone Institutional Advisory LLC boosted its position in shares of Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares during the period. Magnus Financial Group LLC boosted its position in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares during the period. Finally, Choreo LLC boosted its position in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after acquiring an additional 7,080 shares during the period. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.